Chemists uncover 'green' catalysts with promise for cheaper drug production

The synthesis of drugs usually relies on the use of catalysts and the expense of the catalysts influences the ultimate cost of the drug. If the catalyst is toxic, as it usually is when platinum-metals such as ruthenium, rhodium and palladium are used, then it must be removed completely from the synthesized product using costly purification techniques.

"With a cheaper and less toxic catalyst, like iron, these drawbacks are avoided," says Professor Robert Morris. The study appeared online in Chemistry - A European Journal on April 9.

The successful use of iron as a catalyst in place of the more commonly used ruthenium is surprising since iron has been considered to be a "base metal" of low catalytic activity. The successful trick was to prepare a complex of iron with a structure similar to the most active ruthenium catalyst, says Morris.

Chemical catalysts are generally known for their ability to speed up a reaction but they can also influence the structure of the chemical that is produced in that reaction, says Morris. Catalysts used in the synthesis of a chemical used as a drug or fragrance are most valuable when they cause the production of the chemical in one structural form and not the mirror image of that form (i.e. producing a left-handed form and not the right-handed one).

The catalyst was made by attaching to iron, in its "ferrous" state, an organic molecule that contains carbon, hydrogen, phosphorus and nitrogen with the atoms arranged in exclusively a right-handed structural form. The catalyst is used in small amounts to convert a large amount of inexpensive ketone to a large amount of the valuable alcohol product in just the left-handed form. This process is called asymmetric transfer hydrogenation.

Source: University of Toronto (news : web)